Merck Swings To Quarterly Loss On Cidara Deal

Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.

Earnings Scheduled For April 30, 2026

Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push

Organon momentum score jumps as Sun Pharma's $11.75B all-cash acquisition deal boosts outlook, lifting stock trends across timeframes.

Merck & Co Raises FY2026 Adj EPS Guidance from $5.00-$5.15 to $5.04-$5.16 vs $5.11 Est; Raises FY2026 Sales Guidance from $65.500B-$67.000B to $65.800B-$67.000B vs $66.614B Est.

Merck & Co (NYSE:MRK) raises FY2026 Adj EPS guidance from $5.00-$5.15 to $5.04-$5.16 vs $5.11 analyst estimate. Raises FY2026 sales outlook from $65.500 billion-$67.000 billion to $65.800 billion-$67.000 billion vs

Merck & Co Q1 Adj. EPS $(1.28) Beats $(1.51) Estimate, Sales $16.286B Beat $15.823B Estimate.

Merck & Co (NYSE:MRK) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.51) by 15.23 percent. This is a 157.66 percent decrease over earnings of $2.22 per share from the same

The Dow Jones Earnings Showdown: 11 Blue‑Chips Step Up This Week

It's a big week for the Dow Jones Industrial Average with 11 of the 30 components reporting earnings. Here's the stocks on watch.

Organon To Be Acquired By Sun Pharma In $11.75B Deal, OGN Stock Spikes Nearly 17% On Robinhood 24-Hour Market

Organon & Co. has agreed to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion, offering shareholders a 103% premium and marking a major step in Sun Pharma's global expansion into women's health and biosimilars.

Merck's Waiting Period Expires Under Hart-Scott-Rodino Antitrust Improvements Act To Acquire Terns Pharmaceuticals

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.

Merck's Enflonsia Receives Medicines And Healthcare Products Regulatory Agency Approval To Prevent Respiratory Syncytial Virus Lower Respiratory Tract Disease In Newborns And Infants

https://www.gov.uk/government/news/enflonsia-clesrovimab-cfor-approved-to-prevent-rsv-in-newborns-and-infants?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=71f4e4ad-cb30-40f5-bb75-295f2ecac91